Mar 31 2010
Will the newly signed health care legislation create a major shift in
how pharmaceutical brand decisions are made? The bill will increase
access to health insurance, but many believe the practice of medicine is
already in transition, and the bill signed by President Obama will
simply accelerate changes already being implemented.
“The days of payors just accepting or rejecting the
various treatment patterns devised by doctors and institutions are
ending. The new legislation will increase access to health care, but
basing treatment on what's been shown to work will control costs and
improve quality.”
A recent New York Times article reported that even before the new Health
Care Reform Bill was signed, a 'quiet revolution is transforming how
medical care is delivered in this country'. According to the Medical
Group Management Association, the majority of physicians, which as
recently as three years ago predominantly worked in physician-owned, are
now employed by hospitals.
Dr. Ross Weaver, president of DDI, notes, "Medical practices, as
corporate entities, are inserting themselves currently into decisions
physicians make when deciding what the best care to provide to their
patients is. This includes prescribing practices. For pharmaceutical
companies, medical practice entities are the new player in town."
Medical practice entities influence individual physician prescribing by
negotiating with payors to provide additional payments when an agreed
upon percentage of patients in a practice meet specific clinical
outcomes. For example, if more than 60% of patients with diabetes have
their HbA1C less than 7 mg/dl, the practice receives additional
payments. Similarly, if a practice reduces the number of emergency room
visits and hospitalizations among their patients with asthma, the
practice receives additional payments.
According to Dr. Daniel Hoffman, president of Pharmaceutical Business
Research Associates, "The days of payors just accepting or rejecting the
various treatment patterns devised by doctors and institutions are
ending. The new legislation will increase access to health care, but
basing treatment on what's been shown to work will control costs and
improve quality."
While this was the original goal of HMOs and managed care organizations
when founded back in the 1970s, only recently do a sufficient percentage
of practices and payors have the necessary electronic record keeping
capabilities to determine which approaches truly lower the costs of
care. While many large payors continue to focus on lowering drug costs,
regional payors have created niches for their businesses by integrating
claims, electronic health records (EHR) and lab feeds into a single
database. They have data-metrics analysts on staff whose jobs it is to
mine the data, looking for ways to lower the cost of care, not just the
cost of drugs.
Source:
Drug Development Insights (DDI)